> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 4 Priority Review Vouchers Redeemed: FDA
- URL: https://www.fdaweb.com/4-priority-review-vouchers-redeemed-fda/
- Published: 2024-01-24T12:00:00.000Z
- Updated: 2026-09-14T14:21:04.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156206

*Federal Register* notices: FDA announces that a priority review voucher was redeemed in the approval of the following products:

- Astellas Pharma’s Veozah (fezolinetant), indicated for treating moderate to severe vasomotor symptoms, or hot flashes, caused by menopause (see notice [here](https://www.govinfo.gov/content/pkg/FR-2024-01-23/pdf/2024-01163.pdf?ref=fdaweb.com).)
- Novartis’ Cosentyx (secukinumab) for treating active non-radiographic axial spondyloarthritis (see notice [here](https://www.govinfo.gov/content/pkg/FR-2024-01-23/pdf/2024-01164.pdf?ref=fdaweb.com)).
- Bristol Myers Squibb’s Zeposia (ozanimod) for treating adults with moderately to severely active ulcerative colitis (see notice [here](https://www.govinfo.gov/content/pkg/FR-2024-01-23/pdf/2024-01160.pdf?ref=fdaweb.com)).
- Jazz Pharmaceuticals’ Xywav (calcium, magnesium, potassium, and sodium oxybates) for treating cataplexy or excessive daytime sleepiness (see notice [here](https://www.govinfo.gov/content/pkg/FR-2024-01-23/pdf/2024-01156.pdf?ref=fdaweb.com)).